Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Halozyme Therapeutics, Inc. (HALO)
Price$115.13Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.3M | $660.1M | $443.3M | $267.6M | $196.0M | $151.9M | $316.6M | $146.7M | $135.1M | $75.3M | $54.8M | $42.3M | $56.1M | $13.6M | $13.7M |
| Gross profit | $1.17B | $855.9M | $636.9M | $520.8M | $361.9M | $224.2M | $150.4M | $141.7M | $285.5M | $113.5M | $105.8M | $52.6M | $48.6M | $41.2M | $55.8M | $12.6M | $13.4M |
| Gross margin | 83.62% | 84.30% | 76.80% | 78.90% | 81.64% | 83.79% | 76.76% | 93.33% | 90.16% | 77.36% | 78.35% | 69.83% | 88.60% | 97.42% | 99.54% | 92.77% | 97.72% |
| Research & development | $81.5M | $79.0M | $76.4M | $66.6M | $35.7M | $34.2M | $140.8M | $150.3M | $150.6M | $150.8M | $93.2M | $79.7M | $96.6M | $70.0M | $57.6M | $51.8M | $56.6M |
| Operating expenses | $927.6M | $463.8M | $491.7M | $392.6M | $167.4M | $123.3M | $263.6M | $221.2M | $235.6M | $229.9M | $162.5M | $138.4M | $135.2M | $96.0M | $75.9M | $67.9M | $72.1M |
| Operating income | $469.0M | $551.5M | $337.6M | $267.5M | $275.9M | $144.3M | −$67.6M | −$69.3M | $81.0M | −$83.2M | −$27.5M | −$63.0M | −$80.4M | −$53.6M | −$19.8M | −$54.3M | −$58.5M |
| Operating margin | 33.58% | 54.32% | 40.71% | 40.53% | 62.24% | 53.91% | −34.50% | −45.65% | 25.58% | −56.72% | −20.33% | −83.68% | −146.78% | −126.70% | −35.37% | −398.25% | −427.60% |
| EBITDA | $480.4M | $561.7M | $348.7M | $274.0M | $278.9M | $147.5M | −$63.5M | −$66.9M | $83.2M | −$80.8M | −$25.8M | −$61.3M | −$79.2M | −$52.5M | −$18.7M | −$52.7M | −$57.0M |
| EBITDA margin | 34.40% | 55.33% | 42.04% | 41.51% | 62.91% | 55.14% | −32.42% | −44.08% | 26.27% | −55.08% | −19.08% | −81.34% | −144.54% | −124.15% | −33.42% | −387.18% | −417.04% |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M | $129.1M | −$72.2M | −$80.3M | $63.0M | −$103.0M | −$32.2M | −$68.4M | −$83.5M | −$53.6M | −$19.8M | −$53.2M | −$58.4M |
| Net profit margin | 22.69% | 43.74% | 33.96% | 30.62% | 90.84% | 48.24% | −36.86% | −52.90% | 19.89% | −70.23% | −23.86% | −90.76% | −152.34% | −126.53% | −35.25% | −390.79% | −426.88% |
| Basic EPSper basic share | $2.64 | $3.50 | $2.13 | $1.48 | $2.86 | $0.95 | -$0.50 | -$0.56 | $0.46 | -$0.81 | -$0.25 | -$0.56 | -$0.74 | -$0.48 | -$0.19 | -$0.56 | -$0.67 |
| Diluted EPSper diluted share | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | -$0.50 | -$0.56 | $0.45 | -$0.81 | -$0.25 | -$0.56 | -$0.74 | -$0.48 | -$0.19 | -$0.56 | -$0.67 |
Owners
Reported shareholders
11.64%of listed shares
BlackRock, Inc.13.27M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 11.64%13.27M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.69%5.35M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 4.65%5.3M shares |
STATE STREET CORP | 4.54%5.18M shares |
Invesco Ltd. | 2.79%3.18M shares |
MORGAN STANLEY | 2.48%2.83M shares |
Boston Partners | 2.43%2.77M shares |
BANK OF AMERICA CORP /DE/ | 2.40%2.74M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.21%2.52M shares |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2.20%2.51M shares |
SNYDER CAPITAL MANAGEMENT L P | 2.10%2.4M shares |
DIMENSIONAL FUND ADVISORS LP | 1.83%2.09M shares |
D. E. Shaw & Co., Inc. | 1.76%2.01M shares |
Assenagon Asset Management S.A. | 1.75%2M shares |
LOS ANGELES CAPITAL MANAGEMENT LLC | 1.70%1.94M shares |
ROYAL LONDON ASSET MANAGEMENT LTD | 1.59%1.81M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.49%1.7M shares |
ALLIANCEBERNSTEIN L.P. | 1.49%1.7M shares |
TWO SIGMA INVESTMENTS, LP | 1.45%1.65M shares |
UBS Group AG | 1.31%1.49M shares |
Percentages use 114.04M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | Krishnan MaheshDirector | SellCommon Stock | 7.3K | $75.00 | $547.8K | 14.5K |
| Jun 3, 2026Form 4 · 10b5-1 | Torley HelenPRESIDENT AND CEO | SellCommon Stock | 6.1K | $69.69 | $425.1K | 767.8K |
| Jun 3, 2026Form 4 · 10b5-1 | Torley HelenPRESIDENT AND CEO | SellCommon Stock | 2.0K | $68.74 | $137.5K | 773.9K |
| Jun 3, 2026Form 4 · 10b5-1 | Torley HelenPRESIDENT AND CEO | SellCommon Stock | 1.5K | $67.68 | $101.5K | 775.9K |
| Jun 3, 2026Form 4 · 10b5-1 | Torley HelenPRESIDENT AND CEO | SellCommon Stock | 400 | $66.37 | $26.5K | 777.4K |
Community posts
Halozyme prices a larger $1.3 billion convertible financing
Halozyme ($HALO) increased its convertible-note offering to $1.3 billion from $1.05 billion and set a 1.50% coupon. The notes mature in 2033 and initially convert at approximately $139.84 per share, a 27.5% premium to the reference share pr ...
Halozyme proposes $1.05 billion convertible refinancing
Halozyme ($HALO) announced plans to sell $1.05 billion of convertible senior notes due in 2033, with an option for initial purchasers to buy a further $150 million. The securities would be senior unsecured obligations paying interest twice ...
